Hematogenix's MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma
FDA approval validates assay's role in first CELMoD therapy for multiple myeloma.
What changed
FDA approval validates assay's role in first CELMoD therapy for multiple myeloma.
Why it matters
FDA approval validates assay's role in first CELMoD therapy for multiple myeloma. — impact context not separately stored; see What changed.
← Dashboard
Aug 19, 2026 01:45 PM ET